Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00309 JCO Precision Oncology no. 6 (2022) e2200309. Published online November 3, 2022. PMID: 36331241 Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing? Tira J. Tan , MBBS1,2xTira J. TanSearch for articles by this author; J. Lynn Fink, PhD3,4xJ. Lynn FinkSearch for articles by this author; Timothy K. Tay , MBBS5xTimothy K. TaySearch for articles by this author; Binny Jaradi , BSc3xBinny JaradiSearch for articles by this author; Nathan Stone, BBiotech3xNathan StoneSearch for articles by this author; Paul Waring , MBBS, PhD3xPaul WaringSearch for articles by this author; Kevin M. Koo , PhD3xKevin M. KooSearch for articles by this author; Puay Hoon Tan, MBBS, MD5xPuay Hoon TanSearch for articles by this author; Daniel S. Tan , PhD1,2xDaniel S. TanSearch for articles by this author; and Rebecca A. Dent, MD1,2xRebecca A. DentSearch for articles by this author Show More 1Division of Medical Oncology, National Cancer Centre, Singapore, Singapore2Oncology Academic Clinical Program, Duke-NUS Medical School, Singapore, Singapore3XING Genomic Services, Brisbane, Australia4The University of Queensland Diamantina Institute, Brisbane, Australia5Division of Pathology, Singapore General Hospital, Singapore, Singapore https://doi.org/10.1200/PO.22.00309 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologySUPPORTT.J.T. is supported by the NMRC research training fellowship. XING Genomic Services provided the oncoReveal assays used in this case report.AUTHOR CONTRIBUTIONSConception and design: Tira J. Tan, J. Lynn Fink, Rebecca A. DentFinancial support: Daniel S. TanAdministrative support: Tira J. Tan, J. Lynn Fink, Timothy K. Tay, Kevin M. Koo, Rebecca A. DentProvision of study materials or patients: Tira J. Tan, J. Lynn Fink, Timothy K. Tay, Paul Waring, Puay Hoon Tan, Rebecca A. DentCollection and assembly of data: Tira J. Tan, J. Lynn Fink, Timothy K. Tay, Binny Jaradi, Nathan Stone, Paul Waring, Rebecca A. DentData analysis and interpretation: Tira J. Tan, J. Lynn Fink, Paul Waring, Kevin M. Koo, Puay Hoon Tan, Daniel S. Tan, Rebecca A. DentManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Tira J. TanHonoraria: AstraZeneca, Roche/Genentech, Novartis, MSD OncologyConsulting or Advisory Role: AstraZeneca, Lilly, Novartis, MSD Oncology, Everest Medicine, DKSHSpeakers' Bureau: NovartisResearch Funding: Bayer (Inst), Novartis (Inst), AstraZeneca (Inst), Odonate Therapeutics (Inst), Seattle Genetics (Inst), Roche/Genentech (Inst), Daiichi Sankyo/Astra Zeneca (Inst), Sanofi (Inst)Travel, Accommodations, Expenses: AstraZenecaJ. Lynn FinkEmployment: Xing TechnologiesStock and Other Ownership Interests: Xing TechnologiesPaul WaringEmployment: AstraZenecaLeadership: Pillar Biosciences, Xing Technologies, ORI healthcareStock and Other Ownership Interests: Roche/Genentech, Roche, Pillar Biosciences, Xing TechnologiesConsulting or Advisory Role: Pillar Biosciences, Xing Technologies, ORI HealthcareTravel, Accommodations, Expenses: Xing Technologies, AstraZenecaKevin M. KooEmployment: Xing TechnologiesLeadership: Xing TechnologiesPuay Hoon TanHonoraria: AstraZenecaConsulting or Advisory Role: AstraZenecaDaniel S. TanHonoraria: Bristol Myers Squibb, Takeda, Novartis, Roche, PfizerConsulting or Advisory Role: Novartis, Merck, Loxo, AstraZeneca, Roche, Pfizer, C4 TherapeuticsResearch Funding: Novartis (Inst), GlaxoSmithKline (Inst), AstraZeneca (Inst)Travel, Accommodations, Expenses: Pfizer, Boehringer Ingelheim, RocheRebecca A. DentHonoraria: Roche/Genentech, AstraZeneca, Pfizer, MSD, Eisai Europe, LillyConsulting or Advisory Role: Roche, Pfizer, Merck, Eisai, AstraZeneca, NovartisResearch Funding: AstraZeneca, RocheTravel, Accommodations, Expenses: Roche, Pfizer, Amgen, Merck, AstraZenecaNo other potential conflicts of interest were reported.